Login / Signup

'Triple therapy' (elexacaftor, tezacaftor, ivacaftor) skin rash in patients with cystic fibrosis.

May Khei HuGenna WoodOwen Dempsey
Published in: Postgraduate medical journal (2020)
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • cystic fibrosis
  • chronic kidney disease
  • prognostic factors
  • peritoneal dialysis
  • stem cells
  • cell therapy
  • patient reported